Carisma Starts Phase 1 Study of Combo in Patients with HER2 Overexpressing Solid Tumors

 Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA®

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in its Phase I clinical trial that will test the safety and tolerability of the Company's lead product candidate, CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) in combination with Merck's anti-PD1 therapy KEYTRUDA® (pembrolizumab) for the treatment of HER2 overexpressing cancers.

https://finance.yahoo.com/news/carisma-therapeutics-announces-first-patient-123000640.html